Clinical trials: Bladder Carcinoma
Muscle-invasive Urothelial Carcinoma of the Bladder
Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer
This is a Phase 2, single-center, open-label, non-randomized study in patients with MIBC who cannot receive or refuse to receive cisplatin-based chemotherapy. Patients will be consecutively enrolled and treated.
- Trial name
- SURE-02 (NCT05535218)
- Testing
- Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Claudia Guerrieri
Urinary Bladder Neoplasm
SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Bladder carcinoma (BC) is the 13th leading cause of cancer mortality worldwide . In Egypt, BC is the third common malignant tumor.
- Trial name
- NCT05429710
- Volunteers
- 60 people
- Sponsor
- Sohag University
Cervical Carcinoma, Endometrial Carcinoma
Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy
This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation…
- Conditions
- Cervical Carcinoma, Endometrial Carcinoma, Overactive Bladder, Voiding Disorders
- Trial name
- NCT07662824
- Testing
- Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Mayo Clinic
Urinary Bladder Neoplasms, Transurethral Resection of the Bladder
Postoperative Quality of Recovery After Transurethral Resection of the Bladder
Transurethral resection of the bladder (TURB) is often performed as an outpatient procedure so high-quality postoperative recovery is particularly important.
- Conditions
- Urinary Bladder Neoplasms, Transurethral Resection of the Bladder, Postoperative Recovery
- Trial name
- NCT02534623
- Testing
- Spinal anesthesia, General anesthesia, bupivacaine
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- General Hospital Zadar
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
This phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back (recurrent), spread to nearby tissues or lymph…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT03237780
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 21 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or…
- Trial name
- NCT02302807
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Docetaxel, Paclitaxel
- Where
- 217 sites in United States, Australia and 27 more
- Volunteers
- 931 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
This is a multi-site, randomized, prospective, open-label phase II study. Patients in this study will have localized (cT3-cT4), or metastatic bladder cancer with a symptomatic, intact primary bladder tumor.
- Trial name
- NCT03150836
- Testing
- Durvalumab, Tremelimumab, Radiation Therapy
- Where
- United States
- Sponsor
- Terence Friedlander, MD
Invasive Bladder Cancer
MRI and Bladder Cancer Chemotherapy
This is a prospective study of pretreatment DW-MRI to identify potential imaging biomarkers predictive of response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
- Trial name
- NCT01922232
- Where
- United States
- Sponsor
- NYU Langone Health
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Prostate Carcinoma, Kidney Cancer
Development of Diagnostics and Treatment of Urological Cancers
The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation…
- Conditions
- Prostate Carcinoma, Kidney Cancer, Urothelial Carcinoma, Testicular Cancer
- Trial name
- DEDUCER (NCT02994758)
- Testing
- Personalised treatment
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Helsinki University Central Hospital
Bladder Cancer
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in addition to the standard chemotherapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium by estimating…
- Trial name
- NCT00246974
- Testing
- Gemcitabine, Cisplatin, Gefitinib
- Where
- 14 sites in Germany
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Urinary Bladder Tumor
Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor
Bladder cancer is a common urological malignant disease. Patients with bladder cancer will first be managed with transurethral resection (TUR) of bladder tumor.
- Trial name
- NCT01581723
- Testing
- Monopolar diathermy, Bipolar diathermy
- Where
- 2 sites in Hong Kong
- Volunteers
- 150 people
- Sponsor
- Chinese University of Hong Kong
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or…
- Trial name
- NILE (NCT03682068)
- Testing
- Durvalumab, Tremelimumab, Cisplatin + Gemcitabine
- Where
- 222 sites in United States, Argentina and 20 more
- Volunteers
- 1,246 people
- Sponsor
- AstraZeneca
Bladder Cancer
Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy
The investigators proposes a prospective cohort study in patients with high risk bladder cancer who have opted for radical cystectomy.
- Trial name
- NCT02039310
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Michigan
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Bladder Cancer
Complications of Transurethral Resection of the Bladder Tumour
This is a prospective study enrolling consecutive patients who undergo transurethral resection of the bladder tumour (TURBT) aimed at determination of a safety of the procedure.
- Trial name
- ComTUR (NCT03029663)
- Testing
- Transurethral resection of the bladder tumour
- Where
- Poland
- Volunteers
- 983 people
- Sponsor
- Medical University of Warsaw
Bladder Cancer
Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography
To evaluate the diagnostic accuracy of CEUS for the preoperative staging of bladder cancer, which would benefit the implementation of efficient therapeutic strategies.
- Trial name
- NCT05204108
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer
The Global En Bloc Resection of Bladder Tumour Registry
The study aims to collect data on ERBT globally in order to clarify its role in the management of bladder cancer over a 5-year observation period.
- Trial name
- NCT04934540
- Testing
- En bloc resection of bladder tumour
- Where
- 2 sites in Hong Kong
- Volunteers
- 2,000 people
- Sponsor
- Chinese University of Hong Kong
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate or Bladder Cancer
Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.
Pelvic lymph node dissection (PLND) is the most accurate staging tool to determine lymph node involvement in prostate and bladder cancer.
- Trial name
- NCT02001857
- Testing
- 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- University Hospital, Ghent